WeVote
Log In

Bill

Bill

HM 58

STUDY PSILOCYBIN-BASED MEDICATION TREATMENT

2025 Regular Session Introduced by Day Hochman-Vigil

New Mexico would study psilocybin-based treatments for mental health conditions to explore therapeutic potential and regulatory pathways.

action postponed indefinitely
#health&healthfacilities #memorials #other
0
WeVote Research Nonpartisan
Bill Summary · HM 58

Legislative bill overview

HM 58 is a memorial bill requesting that New Mexico conduct a comprehensive study on psilocybin-based medications for treating mental health conditions, including depression, anxiety, and PTSD. The bill calls for research into efficacy, safety, and potential regulatory pathways for clinical use within the state.

Why is this important

Psilocybin research has shown promising preliminary results in clinical trials for treatment-resistant mental illness, but remains federally controlled with limited research opportunities. A state-level study could position New Mexico as a leader in psychedelic medicine research and potentially inform future therapeutic options for residents with conditions resistant to conventional treatments.

Potential points of contention

  • Federal-state legal conflict: Psilocybin remains a Schedule I controlled substance federally, creating complications for state-level research authorization and funding
  • Research feasibility concerns: Establishing legitimate clinical research infrastructure for controlled substances requires significant federal coordination and oversight, raising questions about practical implementation
  • Public perception and stigma: Association with recreational drug use may generate opposition from constituencies concerned about normalizing psychedelics, despite clinical research distinctions

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.